– SOUTH KOREA, Seoul – NurrOn Pharmaceuticals Inc., a clinical-stage biopharmaceutical company dedicated to developing novel, targeted therapeutics for the treatment of Parkinson’s disease and other Nurr1-related human disorders, today announced the appointment of Dr. Almira Chabi (MD, EGMP) to its Board of Directors, effective November 24, 2023.
About Dr. Almira Chabi
Dr. Almira Chabi who is currently CMO and CDO at HanAll Pharmaceutical International brings a wealth of experience and expertise to NurrOn’s board with a successful track record as a physician-scientist with deep experiences as an executive as well as board member. Dr. Chabi has led programs across multiple therapeutic areas including neurology, immunology, oncology, and ophthalmology as well as applications of artificial intelligence. She is also serving on the Scientific and Medical Research Funding Grants Working Group at the California Institute for Regenerative Medicine.
Dr. Chabi previously held the position of VP and Global Therapeutic Area Head for Glaucoma & Neuroprotection as well as Lead for Artificial Intelligence Programs at Santen. Before Santen, she worked at Genentech including a senior role on a pivotal Phase III program encompassing over 20 countries. Dr. Chabi began her pharmaceutical career at Merck in the Neuroscience & Ophthalmology Clinical Research Group, working on a range of projects within Ophthalmology as well as Neuroscience leading to multiple successful NDA filings.
In addition to expertise in drug discovery and development, as well as biomarker and device development, she has been extensively involved in due diligence for business development and venture capital teams. Dr. Chabi is also an alumna of Wharton Business School’s Executive Management Program and has served as a board representative for multiple companies.
Dr. Chabi said, “I am honored to be a part of NurrOn’s Board of Directors. NurrOn is a company that has consistently demonstrated a deep commitment to discovering and developing innovative treatments that have the potential to improve clinical outcomes for Parkinson’s patients. I look forward to working collaboratively with the board and the executive team to contribute to the continued growth and success of the organization.”
About NurrOn Pharmaceuticals
NurrOn Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing novel, targeted therapeutics for the treatment of Parkinson’s disease (PD) and other Nurr1-related incurable human disorders. Through targeting Nurr1, the master regulator for dopaminergic neuron development and maintenance, we aim to develop a paradigm-changing PD treatment to improve patients’ quality of life. While currently there are only symptomatic treatment options for patients with PD, there have not been any successful therapies to slow or prevent the progression of the disease. We believe that disease-modifying therapies will be achieved by targeting Nurr1, which has generated supportive data as a new druggable PD target. NurrOn was awarded a substantial grant from the Michael J. Fox Foundation in support of the Phase 1 clinical trial of ATH-399A/HL192, which that initiated in the second half of 2023.
For more information: https://nurronpharma.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
